Adalvo announces successful DCP submission for Gralise®

04 November 2021

We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1 2023.

Gralise® is a one-of-a-kind Gabapentin ER formulation that is originally marketed by our sister company Almatica in the US. Our brand is approved in the treatment of postherpetic neuralgia and offers significant patient convenience compared to traditional Gabapentin IR formulations. Apart from reduced pill-burden we offer readily available and proven medico-marketing materials to our partners. Gralise® is selling close to $150mio in the US.

With this achievement we add a new milestone in executing Adalvo’s target of providing a boutique portfolio to our partners across the globe. Adalvo is the exclusive owner of this asset for all ex-US regions which further underpins our differentiated portfolio strategy.